Extended Data Fig. 6: Regression of established NRAS driven melanoma tumors by combined inhibition of MEK1/2 plus chloroquine.
a. The growth of an NRAS-mutated melanoma (NCI515677) PDX was assessed over 21 days in mice treated with: 1. vehicle (Control), 2. trametinib (1 mg/kg), 3. chloroquine (25 mg/kg) or; 4. the combination of both agents at the aforementioned doses as indicated. n = 4 for all treatment groups except combination of both agents n = 5. Center values are the mean; statistical testing was performed by two-sided t-test; ***p < 0.001 vs. control; tttp < 0.001 vs. trametinib. Error bars represent SD. b-e. The percentage weight change of HCI-Mel002 NRAS-mutated PDX was assessed over 21 days in mice treated with: b. vehicle (Control), c. trametinib (1 mg/kg), d. chloroquine (50 mg/kg) or; e. the combination of both agents at the aforementioned doses as indicated. However, side-effects of facial rash and hair loss were noted.
